According to the Zhitong Finance App, Touyun Biotech (01332) announced its 2026 interim results, with gross profit of HK$9.116 million, a year-on-year narrowing of 32.71%; profit attributable to company owners was about HK$198 million, an increase of about 16.6 times over the previous year; profit per share was 7.05 HK cents.

According to the announcement, the increase in profit is mainly due to an increase in fair value returns on financial assets that include profit and loss at fair value.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.